Radyoaktif İyot Dirençli Diferansiye Tiroid Kanserinde Sorafenib: Uzun Dönem Tecrübe ile Gerçek Yaşam Verisi

Abstract

Amaç: Sorafenib radyoaktif iyot (RAİ) dirençli metastatik diferansiye tiroid kanseri (DTK) hastalarındaki standart tedavilerden biridir. Bu araştırmada, sorafenibin RAİ dirençli metastatik DTK hastalarındaki uzun dönem sonuçlarının sunulması amaçlanmıştır. Gereç ve Yöntem: 01.01.2014-31.12.2019 tarihleri arasında RAİ dirençli metastatik DTK tanısı ile takipli hastaların kayıtları geriye dönük olarak incelendi. Genel sağkalım (GSK), progresyonsuz sağkalım (PSK), yanıt oranları ve güvenlik profili analiz edildi. Bulgular: Araştırmaya toplamda 19 hasta dahil edildi. Hastaların çoğunda (%80) papiller tiroid kanseri mevcuttu. On sekiz aylık ortanca takipte, PSK ve GSK sırasıyla 10,9 ve 41 ay olarak bulundu. Objektif yanıt oranı ve hastalık kontrol oranı sırasıyla %36 ve %68 idi. Dokuz hastada (%45) sorafenib ilişkili yan etki görüldü. Sonuç: Bu uzun dönem gerçek yaşam deneyimi verisi, sorafenib ile tedavi edilen RAİ dirençli metastatik DTK hastalarında GSK’nin 3 yıldan daha uzun olduğunu gösterdi. Diğer taraftan, yan etki görülme oranı sorafenibin faz-3 çalışmasındakinden daha azdı.

Keywords

• Tiroid
• Tirozin Kinaz İnhibitörü
• Radyoaktif İyot Dirençli

Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience

Abstract

Objectives: Sorafenib is one of the standard anti-cancer drugs in the treatment of radioactive iodine refractory (RR) metastatic differentiated thyroid cancer (DTC). In this study, we aimed to present a long-term real-life experience of sorafenib in the treatment of (RR) metastatic (DTC). Materials and Methods: We retrospectively searched the patients’ records for RR metastatic DTC patients treated with sorafenib in a tertiary cancer center between 01.01.2014 and 31.12.2019. Progression-free survival (PFS), overall survival (OS), response rates, and safety profile of sorafenib were assessed. Results: A total of 19 patients were included in this study. The majority of patients had papillary thyroid cancer (80%). With a median follow-up of 18 months, the median PFS and OS were 10.9 and 41 months, respectively. The objective response rate and disease control rate were 36% and 68%, respectively. Nine patients (45%) reported any adverse events (AEs) with sorafenib. Conclusion: This long-term real-life experience study showed that the median OS was longer than 3 years in RR metastatic DTC patients treated with sorafenib. On the other hand, AEs rates were lower in our study than in the pivotal phase III trial of sorafenib in RR DTC patients

Keywords

• Thyroid
• Tyrosine Kinase Inhibitor
• Radioactive Iodine Refractory

References

1. 1. WHO. GLOBOCAN 2020 [cited 2020 29.12.2020]. A vailable from: https:// gco.iarc.fr/.
2. 2. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.
3. 3. Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67:501-508.
4. 4. Shobab L, Gomes-Lima C, Zeymo A, et al. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer. Thyroid. 2019;29:1262-1268.
5. 5. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630.
6. 6. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-328.
7. 7. NCCN. Thyroid Cancer 2020 [cited 2020 29.12.2020]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
8. 8. Oh HS, Shin DY, Kim M, et al. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study. Thyroid. 2019;29:1804-1810.